Abstract:More than 10% of nasopharyngeal cancer (NPC) patients develop local recurrence after definitive radiotherapy or chemoradiation. Re-irradiation (re-RT) with X-ray-based intensity-modulated radiotherapy (IMXT) is the most accepted treatment for salvaging locally recurrent NPC (LR-NPC) especially for those at locally advanced stages. However, the reported 2-year overall survival (OS) rates only ranged between 45∼60% for locally advanced LR-NPC after salvage IMXT largely due to treatment-induced toxicities. Due to its inherent physical and biological advantages, carbon-ion radiotherapy (CIRT) is feasible and potentially effective for LR-NPC. Here we report the 1-year outcomes of our phase I/II trial in terms of survival, disease control, and toxicities of LR-NPC patients treated at the maximal tolerable dose (MDT) of CIRT re-RT. This open-label single arm phase I/II trial enrolled pathologically and/or clinically confirmed LR-NPC (age 18∼70 years) diagnosed >12 months after the completion of initial IMXT. In the phase I study, the Time-to-Event Continual Reassessment Method was used to determine, via a dose-escalation scheme, the MTD of CIRT re-RT. The primary end point of the phase II part was patients' 2-year OS. Severe (i.e., Grade 4 or 5) acute and subacute toxicities were analyzed. All patents were treated at 3 Grey Equivalent (GyE) per daily fraction, 5 days a week, using intensity-modulated CIRT with raster-scanning technology. Neoadjuvant chemotherapy (cisplatin + docetaxel or gemcitabine) was recommended for patients with stage III-IVA/B LR-NPC, but concurrent chemotherapy was prohibited. Sixteen patients were accrued to the phase I dose escalating (range 51∼63GyE in 17∼21 fractions) protocol. No patient experienced grade 4 toxicities, thus the MTD was set at 63 GyE/21 fractions, the highest of the protocol dose scheme. Thirty-nine LR-NPC patients (AJCC stage I/II/III/IVA-B disease in 4/8/10/17 patients) were accrued to the phase II study. All patients completed planned 63GyE/21 daily fractions without break. With a median follow-up of 8.4 (range 2.0∼21.9) months, 1 patient died from massive hemorrhage subsequent to mucosal necrosis. The 1-year overall, local progression-free, regional recurrence-free, and distant metastasis free survival rates were 95.0%, 87.1%, 96.4%, and 100%, respectively. No patient experienced acute toxicity of ≥ grade 3. Grade 3 or above late toxicities observed included mucosal necrosis (5.1%), xerostomia (2.6%), hearing loss (5.1%), and temporal lobe necrosis (2.6%). This was the first prospective clinical trial to evaluate the efficacy and safety of CIRT for LR-NPC. Our results suggested that CIRT provided promising OS at 1 year with infrequent severe toxicities.

Clinical advantages of carbon-ion radiotherapy

A Review of Update Clinical Results of Carbon Ion Radiotherapy

Clinical research progress of carbon ion radiotherapy for cancer

Carbon Ion Radiobiology

[The preliminary report of a registration clinical trial of proton and heavy ion irradiation].

Carbon Ion Therapy: A Modern Review of an Emerging Technology

Physics and biomedical challenges of cancer therapy with accelerated heavy ions

3. Research Center for Charged Particle Therapy A. Research on the Use of Heavy Ion Beams for Cancer Radiotherapy. ‡@ Development of Advanced Cancer Radio- Therapy with Charged Particle

Advantages of carbon ion radiotherapy and its application in tumor therapy

Landscape of Carbon Ion Radiotherapy in Prostate Cancer: Clinical Application and Translational Research

Value of carbon-ion radiotherapy for early stage non-small cell lung cancer

Bringing the heavy: carbon ion therapy in the radiobiological and clinical context

Carbon Ion Radiotherapy: An Evidence-Based Review and Summary Recommendations of Clinical Outcomes for Skull-Base Chordomas and Chondrosarcomas

[Comparison of Treatment Planning by Carbon Ion Radiotherapy and by Intensity-Modulated Radiotherapy for Prostatic Adenocarcinoma].

Particle Therapy for Cancers: a New Weapon in Radiation Therapy.

Five-year clinical outcomes of scanning carbon-ion radiotherapy for prostate cancer

Application of Carbon Ion and Its Sensitizing Agent in Cancer Therapy: A Systematic Review

Phase I/II Trial Evaluating Carbon-Ion Radiotherapy for Salvage Treatment of Locally Recurrent Nasopharyngeal Carcinoma

Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma

Carbon Ion Radiotherapy in the Management of Hepatocellular Carcinoma